Beta Bionics, Inc. (Nasdaq: BBNX) released its financial results for the third quarter ended September 30, 2026, and provided updated guidance for the full year ending December 31, 2026. The company reported net sales of $35.5 million for the third quarter, representing a 30% increase compared to the $27.3 million recorded in the same period of 2025. Sales within the Pharmacy Benefit Plan (PBP) channel grew significantly, rising 118% to $13.6 million from $6.2 million in the prior year.
On the balance sheet, Beta Bionics reported cash, cash equivalents, short-term investments, and long-term investments totaling $373.6 million as of September 30, 2026. The company also announced the completion of a public offering of common stock, which raised approximately $161.3 million in net proceeds.
For the full year 2026, the company revised its revenue guidance to an estimated range of $124 million to $126 million. This update reflects a potential revenue deferral impact of up to $8.5 million in the fourth quarter of 2026, as new prospective users may choose to await the launch of the Mint device. The company anticipates that any revenue lost in the fourth quarter will be recaptured during full year 2027. Gross margin guidance was maintained at a range of 58.5% to 59.5%.
Regarding product development, Beta Bionics announced that it has withdrawn its 510(k) application for the 3D Intelligence algorithm. The company intends to submit a revised application in mid-Q4 2026. The company expects to commercialize 3D Intelligence as iLet 3D and Mint 3D in the first half of 2027, with a potential launch in the fourth quarter of 2026 subject to FDA clearance. Additionally, the company completed enrollment for a pivotal trial studying the iLet in adults with type 2 diabetes and plans to initiate a pivotal trial for a next-generation fully-closed loop algorithm in the fourth quarter of 2026.
